小智港股覆盤 | 12月6日
今日,港股三大指數集體下跌。截止收盤,恆生指數跌1.76%,報23349點。國企指數大跌2.14%,報8274點。恆生科技指數大跌3.34%,報5727點。市場約433只個股上漲,1335只個股下跌。成交額突破1700.2億港幣,和昨天同期相比增長2.47%。南下資金淨流入37.16億港幣。

盤面上,海運板塊活躍。東方海外國際漲超3%;中遠海控漲超2%。

航天國防板塊活躍。中航科工漲超1%。

生物科技板塊暴跌。百濟神州跌超13%;康寧傑瑞製藥-B跌超11%;康方生物-B、藥明巨諾-B等多股跌超10%;再鼎醫藥-SB跌超9%。百濟神州A股網上發行最終中籤率約爲0.03515023%;康寧傑瑞製藥-B(09966):全球首款PD-L1皮下注射製劑獲批,叩開商業化大門。

菸草板塊全線走低。思摩爾國際跌超8%。中國電力全日獲市場資金淨流入8.19億元,思摩爾淨流入8.04億元。

CRO板塊暴跌。金斯瑞生物科技跌超8%;藥明康德、藥明生物等多股跌超7%;泰格醫藥跌超6%;康龍化成跌超5%。中信建投:維持金斯瑞生物科技“買入”評級,目標價57.37港元;小摩減持泰格醫藥8.92萬股,每股作價約129.55港元。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.